

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8386239

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CALCILYTIX THERAPEUTICS INC.	01/17/2024
ADRENAS THERAPEUTICS INC.	01/17/2024
PHOENIX TISSUE REPAIR, INC.	01/17/2024
NAVIRE PHARMA, INC.	01/17/2024
VENTHERA, INC.	01/17/2024
MOLECULAR SKIN THERAPEUTICS, INC.	01/17/2024
CANTERO THERAPEUTICS, INC.	01/17/2024
COA THERAPEUTICS, INC.	01/17/2024
PORTAL THERAPEUTICS, INC.	01/17/2024
BRIDGEBIO GENE THERAPY RESEARCH, INC.	01/17/2024
FERRO THERAPEUTICS, INC.	01/17/2024
SUB21, INC.	01/17/2024
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
<b>Street Address:</b>	399 PARK AVENUE, 37TH FLOOR
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022
<b>PROPERTY NUMBERS Total: 70</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	10513497
<b>Patent Number:</b>	11078162
<b>Application Number:</b>	17350066
<b>Patent Number:</b>	11058668
<b>Application Number:</b>	17332359
<b>Patent Number:</b>	11260047
<b>Application Number:</b>	17577479
<b>Application Number:</b>	63487801
<b>Application Number:</b>	63516757

Property Type	Number
Application Number:	63513685
Application Number:	18257450
Application Number:	63488709
Application Number:	63508789
Application Number:	63546133
Application Number:	17613651
Application Number:	17613652
Application Number:	63489168
Application Number:	18546317
Application Number:	63386285
Application Number:	63496873
Application Number:	63416772
Application Number:	63440866
Application Number:	63518242
Application Number:	63518249
Application Number:	63605348
Application Number:	17679841
Application Number:	63490216
Application Number:	18216536
Application Number:	17477198
Application Number:	63497693
Application Number:	63467699
Application Number:	16962552
Application Number:	18551143
Patent Number:	9676837
Patent Number:	9733263
Patent Number:	10921332
Application Number:	17141586
Patent Number:	10695395
Application Number:	18169368
Patent Number:	10669327
Application Number:	17598029
Application Number:	63342993
Patent Number:	10954243
Application Number:	17166737
Patent Number:	11104675
Application Number:	17380943
Application Number:	63492872

Property Type	Number
Application Number:	63517575
Application Number:	63498362
Application Number:	18319350
Patent Number:	11661429
Application Number:	18297698
Application Number:	17393196
Patent Number:	11643420
Application Number:	18295009
Patent Number:	11401246
Application Number:	17843455
Application Number:	17791482
Patent Number:	11547709
Application Number:	18076044
Application Number:	16958022
Patent Number:	11098040
Application Number:	18478186
Patent Number:	11040964
Application Number:	18235234
Application Number:	17638741
Application Number:	17638744
Application Number:	18023270
Application Number:	63609159
Application Number:	63593681

#### CORRESPONDENCE DATA

**Fax Number:** (415)693-2222

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 4156932000

**Email:** crhem@cooley.com

**Correspondent Name:** COOLEY LLP

**Address Line 1:** 3 EMBARCADERO CENTER, 20TH FLOOR

**Address Line 4:** SAN FRANCISCO, CALIFORNIA 94111

<b>ATTORNEY DOCKET NUMBER:</b>	347580-104
<b>NAME OF SUBMITTER:</b>	C. RHEM
<b>SIGNATURE:</b>	/CR/
<b>DATE SIGNED:</b>	01/17/2024

**Total Attachments: 22**

source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page1.tif

source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page2.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page3.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page4.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page5.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page6.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page7.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page8.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page9.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page10.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page11.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page12.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page13.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page14.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page15.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page16.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page17.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page18.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page19.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page20.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page21.tif  
source=Blue Owl - BBIO - Patent Security Agreement - 01.17.2024#page22.tif

## PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of January 17, 2024 (this “**Agreement**”), is entered into by and between each of the grantors listed on the signature pages hereto (each, a “**Grantor**” and collectively, the “**Grantors**”), and Blue Owl Capital Corporation (the “**Assignee**”), as Administrative Agent, pursuant to (i) that certain Pledge and Security Agreement, dated as of January 17, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), among the Assignee, the Grantor and the other grantors party thereto, and (ii) that certain Financing Agreement, dated as of January 17, 2024 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Financing Agreement**”), among the Grantors, certain of the Grantor’s affiliates, the Assignee and certain Lenders party thereto.

Capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or, if not defined therein, the Financing Agreement.

WHEREAS, pursuant to the Security Agreement, each Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the federally registered Patents set forth on Schedule A hereto as of the date hereof, and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors and the Assignee hereby agree as follows:

(a) Grant of Security Interest

(i) Subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantors to the Assignee pursuant to the Security Agreement, each Grantor hereby grants to the Assignee a security interest in and continuing Lien on all of such Grantor’s right, title and interest in, to and under the Patents, whether now owned or existing or hereafter acquired or arising and wherever located, as collateral security for the prompt and complete payment and performance in full when due (whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise) of the Secured Obligations. For the purposes of this Agreement, “**Patents**” means all United States and foreign patents and certificates of invention, or similar industrial property rights and applications for any of the foregoing, including, but not limited to: (i) each patent and patent application referred to in Schedule A hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof, (iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights to sue for past, present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom, and (vii) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit; provided that no Excluded Assets shall be included in the Patents.

(ii) Schedule A hereto contains a true and accurate list of all of the Grantors’ registrations and applications for registration for the Patents in the United States existing as of the date hereof.

(iii) The security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

(b) Modifications

This Agreement or any provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing Agreement. In connection with the foregoing, each Grantor authorizes the Assignee, upon notice to such Grantor, to modify this Agreement without obtaining such Grantor's signature to such modification, to the extent that such modification constitutes an amendment of Schedule A hereto, to add any right, title or interest in any Patents owned or subsequently acquired by such Grantor or to delete any reference to any right, title or interest in any Patents in which such Grantor no longer has or claims any right, title or interest. Each Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any Patent to the security interests and perfection created or contemplated hereby or by the Security Agreement.

(c) Applicable Law

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

(d) Counterparts; Electronic Signatures

This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement. For the purposes of this Section 4, "electronic signature" shall be construed so as to include the electronic signature of each witness, if any, of an electronic signature used to execute this Agreement. The words "execution", "execute", "signed", "signature" and words of like import in this Agreement or in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

(e) CONSENT TO JURISDICTION; WAIVER OF JURY TRIAL

SECTIONS 10.15 (CONSENT TO JURISDICTION) and 10.16 (WAIVER OF JURY TRIAL) OF THE FINANCING AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE, *MUTATIS MUTANDIS*.

*[Signature Page Follows]*

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

**ASSIGNEE:**

**BLUE OWL CAPITAL CORPORATION**

BY: BLUE OWL CREDIT ADVISORS LLC,  
its Investment Advisor

By:   
Name: Meenal Mehta  
Title: Authorized Signatory


Address of Assignee:

Blue Owl Capital Corporation  
399 Park Avenue, 37th Floor  
New York, NY 10022  
Email: [finance@blueowl.com](mailto:finance@blueowl.com);  
[adminagent@blueowl.com](mailto:adminagent@blueowl.com)

with a copy (which shall not constitute notice) to:

Cooley LLP  
1299 Pennsylvania Avenue, NW, Suite 700  
Washington, DC 20004-2400  
Attention: Michael Tollini  
Email: [mtollini@cooley.com](mailto:mtollini@cooley.com)

**CALCILYTIX THERAPEUTICS INC.**


By:   
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**ADRENAS THERAPEUTICS INC.**

By:   
Name: Neil Kumar  
Title: President


Address of Grantor:

1001 William Moore Drive, Ste 100,  
Raleigh, NC 27606  
(NC Flex III Lab)

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer



**PHOENIX TISSUE REPAIR, INC.**


By:  DocuSigned by:  
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**NAVIRE PHARMA, INC.**

By:  DocuSigned by:  
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**VENTHERA, INC.**

By: \_\_\_\_\_  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**PHOENIX TISSUE REPAIR, INC.**

By: \_\_\_\_\_  
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**NAVIRE PHARMA, INC.**


By: \_\_\_\_\_  
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**VENTHERA, INC.**


By: \_\_\_\_\_  
DocuSigned by:  
  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**MOLECULAR SKIN THERAPEUTICS, INC.**

By:  DocuSigned by:  
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**CANTERO THERAPEUTICS, INC.**

By: \_\_\_\_\_  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**COA THERAPEUTICS, INC.**

By: \_\_\_\_\_  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**MOLECULAR SKIN THERAPEUTICS, INC.**


By: \_\_\_\_\_  
Name: Neil Kumar  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**CANTERO THERAPEUTICS, INC.**


By: \_\_\_\_\_  
DocuSigned by:  
  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**COA THERAPEUTICS, INC.**


By: \_\_\_\_\_  
DocuSigned by:  
  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**PORTAL THERAPEUTICS, INC.**

By:  DocuSigned by:  
637F6D78EA384B6...  
Name: Thomas Trimarchi  
Title: President

3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304


c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**BRIDGEBIO GENE THERAPY RESEARCH, INC.**

By:  DocuSigned by:  
Eric David  
896A29748602474  
Name: Eric David  
Title: Chief Executive Officer

Address of Grantor:  
BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer  
Email: Chief Legal Officer


**FERRO THERAPEUTICS, INC.**

By:  DocuSigned by:  
Thomas Trimarchi  
037F0070EA304B9  
Name: Thomas Trimarchi  
Title: President

Address of Grantor:  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304  
Attention: Chief Legal Officer

**SUB21, INC.**

By:  DocuSigned by:  
Neil Kumar  
8013484682A34A7  
Name: Neil Kumar  
Title: President

Address of Grantor:  
1800 Owens St., Suite C-1100,  
San Francisco, CA 94158

c/o BridgeBio Pharma, Inc.  
3160 Porter Drive, Suite 250,  
Palo Alto, CA 94304

Schedule A to PATENT SECURITY AGREEMENT

U.S. Registered Patents and Patent Applications

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Processes for preparing AG-10, its intermediates, and salts thereof	Eidos Therapeutics, Inc.	15/932,327	2/16/2018	US	US10,513,497	12/24/2019	Issued
Processes for preparing AG-10, its intermediates, and salts thereof	Eidos Therapeutics, Inc.	16/676,931	11/7/2019	US	US11,078,162	8/3/2021	Issued
Processes for preparing AG-10, its intermediates, and salts thereof	Eidos Therapeutics, Inc.	17/350,066	6/17/2021	US			Allowed
Methods of treating TTR amyloidosis using AG-10	Eidos Therapeutics, Inc.	16/361,587	3/22/2019	US	US11,058,668	7/13/2021	Issued
Methods of treating TTR amyloidosis using AG-10	Eidos Therapeutics, Inc.	17/332,359	5/27/2021	US			Published
Formulations of AG-10	Eidos Therapeutics, Inc.	16/542,737	8/16/2019	US	US11,260,047	3/1/2022	Issued
Formulations of AG-10	Eidos Therapeutics, Inc.	17/577,479	1/18/2022	US			Published

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Potent Transthyretin (TTR) Stabilization in TTR Amyloidosis Patients Receiving Acoramidis	Eidos Therapeutics, Inc.	63/487,801	3/1/2023	US	NA	NA	Pending
Potent Transthyretin (TTR) Stabilization in TTR Amyloidosis Patients Receiving Acoramidis	Eidos Therapeutics, Inc.	63/516,757	7/31/2023	US	NA	NA	Pending
Extended Release Formulations of Acoramidis	Eidos Therapeutics, Inc.	63/513,685	7/14/2023	US	NA	NA	Pending
Methods of Treating Achondroplasia	QED Therapeutics, Inc.	18/257,450	6/14/2023	US			Pending
Methods of Treating Skeletal Dysplasias	QED Therapeutics, Inc.	63/488,709	3/6/2023	US	N/A	N/A	Pending
Methods of Treating Skeletal Dysplasias	QED Therapeutics, Inc.	63/508,789	6/16/2023	US	N/A	N/A	Pending
Methods of Treating Skeletal Dysplasias	QED Therapeutics, Inc.	63/546,133	10/27/2023	US	N/A	N/A	Pending
Methods of treating cholangiocarcinoma	QED Therapeutics, Inc.	17/613,651	11/23/2021	US			Published



<b>Title</b>	<b>Owner</b>	<b>App. No.</b>	<b>Filing Date</b>	<b>Juris.</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Status</b>
Methods of treating urinary system cancers	QED Therapeutics, Inc.	17/613,652	11/23/2021	US			Published
Deuterated infigratinib compounds	QED Therapeutics, Inc.	63/489,168	3/8/2023	US	N/A	N/A	Pending
Compositions and methods for inhibition of Ras	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	18/546,317	8/14/2023	US			Pending
Compositions and methods for inhibition of Ras	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/386,285	12/6/2022	US			Pending

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Compositions and methods for inhibition of Ras	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/496,873	4/18/2023	US			Pending
Compounds Having A T-Structure Formed By At Least Four Cycles For Use In The Treatment Of Cancer And Other Indications	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/416,772	10/17/2022	US			Pending
Compositions and methods for inhibition of Ras	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/440,866	1/24/2023	US			Pending

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Fused Pyridines for the Treatment of Cancer and Other Indications	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/518,242	8/8/2023	US			Pending
Fused Pyridines for the Treatment of Cancer and Other Indications	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/518,249	8/8/2023	US			Pending
Compositions and Methods for Inhibition of RAS	TheRas, Inc. co-owned with Leidos Biomedical Research, Inc. and Lawrence Livermore National Security, LLC	63/605,348	12/1/2023	US			Pending
Detection of dystroglycan	ML Bio Solutions Inc.	17/679,841	2/24/2022	US			Pending

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Assays for Alpha-Dystroglycan Glycosylation and Methods for Using Same	ML Bio Solutions Inc.	63/490,216	3/14/2023	US	N/A	N/A	Pending
Formulations of triphenyl calcilytic compounds	Calcilytix Therapeutics Inc.	18/216,536	6/29/2023	US			Pending
Triphenyl Calcilytic Compounds For The Treatment Of Autosomal Dominant Hypocalcemia Type 1 (ADH1)	Calcilytix Therapeutics Inc. co-owned with US Department of Health and Human Services	17/477,198	9/16/2021	US			Published
Treatment of Hypoparathyroidism Using Triphenyl Calcilytic Compounds	Calcilytix Therapeutics Inc. co-owned with US Department of Health and Human Services	63/497,693	4/21/2023	US			Pending
Methods of Treating Autosomal Dominant Hypocalcemia Type 1	Calcilytix Therapeutics Inc.	63/467,699	5/19/2023	US	NA	NA	Pending

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Adeno-associated virus gene therapy for 21-hydroxylase deficiency	Adrenas Therapeutics Inc.	16/962,552	1/17/2019	US			Published
Gene Therapies for 21-Hydroxylase Deficiency	Adrenas Therapeutics Inc.	18/551,143	9/18/2023	US			Pending
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	14/236,403	03-Aug-2012	US	9,676,837	13-Jun-2017	Granted
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	14/440,958	06-May-2015	US	9,733,263	15-Aug-2017	Granted
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	15/646,303	11-Jul-2017	US	10,921,332	16-Feb-2021	Granted
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	17/141,586	05-Jan-2021	US			Published
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	16/065,512	22-Jun-2018	US	10,695,395	30-Jun-2020	Granted

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	18/169,368	15-Feb-2023	US			Published
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	16/084,998	14-Sep-2018	US	10,669,327	02-Jun-2020	Granted
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	17/598,029	24-Sep-2021	US			Published
Method For Preparing Modified Collagen Outside A Host Cell	Phoenix Tissue Repair, Inc.	63/342,993	17-May-2022	US			Pending
Substituted heterocyclic inhibitors of PTPN11	Navire Pharma, Inc.	16/401,047	5/1/2019	US	US10,954,243	3/23/2021	Issued
Substituted heterocyclic inhibitors of PTPN11	Navire Pharma, Inc.	17/166,737	2/3/2021	US			Allowed
PTPN11 inhibitors	Navire Pharma, Inc.	16/536,923	8/9/2019	US	US11,104,675	8/31/2021	Issued
PTPN11 inhibitors	Navire Pharma, Inc.	17/380,943	7/20/2021	US			Allowed

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Combination therapy using a PTPN11 inhibitor and a BRAF inhibitor, optionally with EGFR inhibitor	Navire Pharma, Inc. co-owned with BMS	63/492,872	3/20/2023	US			Pending
Combination therapy using a PTPN11 inhibitor and a BRAF inhibitor, optionally with EGFR inhibitor	Navire Pharma, Inc. co-owned with BMS	63/517,575	8/3/2022	US			Pending
Substituted pyridol[3,4-B]indole-1,4-dione compounds for treatment of porphyrias	Portal and BridgeBio	63/498,362	4/26/2023	US	NA	NA	Pending
Methods of preparing gene therapies	BridgeBio Gene Therapy Research, Inc.	18/319,350	5/17/2023	US	NA	NA	Pending
Topical phosphoinositide 3-kinase inhibitors	Venthera, Inc.	16/783,050	2/5/2020	US	US11,661,429	5/20/2023	Issued
Topical phosphoinositide 3-kinase inhibitors	Venthera, Inc.	18/297,698	4/10/2023	US			Pending

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Formulations of phosphoinositide 3-kinase inhibitors	Venthera, Inc.	17/393,196	8/3/2021	US			Pending
Benzoxazinone Compounds as CLK5/7 Dual Inhibitors	Molecular Skin Therapeutics, Inc.	17/037,910	9/30/2020	US	US11,643,420	5/9/2023	Issued
Benzoxazinone Compounds as CLK5/7 Dual Inhibitors	Molecular Skin Therapeutics, Inc.	18/295,009	4/3/2023	US			Pending
Triazole glycolate oxidase inhibitors	Cantero Therapeutics, Inc.	17/255,600	12/23/2020	US	US11,401,246	8/2/2022	Issued
Triazole glycolate oxidase inhibitors	Cantero Therapeutics, Inc.	17/843,455	6/17/2022	US			Pending
Processes For Preparing Triazole Glycolate Oxidase Inhibitors	Cantero Therapeutics Inc.	17/791,482	7/7/2022	US			Pending
Methods of treating disorders associated with castor	CoA Therapeutics, Inc. co-owned with St. Jude Children's Research Hospital, Inc.	16/957,996	6/25/2020	US	US11,547,709	1/10/2023	Issued



Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Methods of treating disorders associated with castor	CoA Therapeutics, Inc. co-owned with St. Jude Children's Research Hospital, Inc.	18/076,044	12/6/2022	US			Pending
Small molecule modulators of pantothenate kinases	CoA Therapeutics, Inc. co-owned with St. Jude Children's Research Hospital, Inc.	16/958,022	6/25/2020	US			Allowed
Compounds with ferroptosis inducing activity and methods of their use	Ferro Therapeutics, Inc.	16/287,805	2/27/2019	US	US11,098,040	8/24/2021	Issued
Compounds with ferroptosis inducing activity and methods of their use	Ferro Therapeutics, Inc.	18/478,186	9/29/2023	US			Pending
Compounds With Ferroptosis Inducing Activity And Methods Of Their Use	Ferro Therapeutics, Inc.	16/803,862	2/27/2020	US	US11,040,964	6/22/2021	Issued

Title	Owner	App. No.	Filing Date	Juris.	Patent No.	Issue Date	Status
Compounds With Ferroptosis Inducing Activity And Methods Of Their Use	Ferro Therapeutics, Inc.	18/235,234	8/17/2023	US			Pending
Benzimidazole and hydrogenated carbazole derivatives as GPX4 inhibitors	Ferro Therapeutics, Inc.	17/638,741	2/25/2022	US			Pending
Pyrido-indole analogues as GPX4 inhibitors	Ferro Therapeutics, Inc.	17/638,744	2/25/2022	US			Pending
Compounds and methods of use	Ferro Therapeutics, Inc.	18/023,270	2/24/2023	US			Pending
Tricyclic sulfonamide compounds	Sub 21, Inc.	63/609,159	12/12/2023	US	NA	NA	Pending
Tricyclic sulfonimine compounds	Sub 21, Inc.	63/593,681	10/27/2023	US	NA	NA	Pending